Life Sciences - Mergers, Acquisitions and Joint Ventures

McGuireWoods has earned an international reputation for mergers and acquisitions work, representing buyers and sellers in acquisitions, divestitures and joint ventures. We have significant experience in a variety of M&A transactions, whether structured as asset or stock deals, and involving enterprises of all sizes. We have also worked with many companies in establishing, drafting and negotiating joint venture or strategic alliance agreements — part of which can be assisting with cost-effective, rapid means of expansion or better leveraging proprietary technology.

In situations in which only part of an enterprise is being sold, we work with clients and their other advisors to organize and analyze relevant due diligence; identify business, operational and legal problems; and develop solutions addressing those needs. We explore and implement financing arrangements; comply with and obtain appropriate clearance under tender offer, registration, proxy and other securities law requirements; identify and resolve other potential legal problems (including tax, antitrust, employee benefits, labor, environmental, liability exposure, real estate, and governmental and other consent or approval issues); and negotiate and draft the implementing agreements, technology licensing and other technology-sharing agreements and documentation.

Our experience includes:

  • Mergers and acquisitions, venture capital, private equity and debt financings, IPOs
  • Intellectual property licensing and technology transfer
  • Contract manufacturing agreements
  • Outsourcing of drug, device and biotechnology product development, manufacturing and marketing
  • Co-development agreements
  • Product manufacturing and supply agreements
  • Co-marketing arrangements
  • Quality agreements
  • CRO and clinical trial agreements

Blogs

The Healthcare Investor


 

CONTACTS

Bart Walker Partner T: +1 704 373 8923

BLOG

FDA Life

Results 1-4 of 4

RESULTS DEPEND ON A VARIETY OF FACTORS UNIQUE TO EACH CASE. PRIOR RESULTS DO NOT GUARANTEE OR PREDICT A SIMILAR OUTCOME.

Representative Matter

Zabel Exits Puritan Products Investment

Representation of Zabel Companies, a private investment firm, in its sale of Puritan Products, a manufacturer of specialty chemicals and custom chemical blends, to Avantor Performance Materials, a portfolio company of New Mountain Capital.
Representative Matter

Paceline Acquires Orthomerica’s Seal PVA Business

Representation of Paceline, Inc., a manufacturer of textiles, chemicals and plastics for the medical industry, in its acquisition of Orthomerica’s Seal PVA business.
Representative Matter

German Life Sciences Company Acquires Medical Device Technologies Company

Representation of a German-based global quality and safety services company in its $7 million acquisition, through its U.S. subsidiary, of a medical device development company.
Representative Matter

CanX Sale of Assets to CannaVest

Representation of CanX, Inc., a developer of synthetically-formulated cannabidiol for use in drug development activities, in its sale to CannaVest Corp., a life sciences company.
Results 1-4 of 4